Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals highlighted the effectiveness of its drug LUPKYNIS for treating lupus nephritis at the EULAR Congress 2024, revealing that patients on a LUPKYNIS-based regimen had significantly reduced steroid use and faster improvements in kidney function compared to traditional therapies. The data underscores the drug’s alignment with medical guidelines recommending it as an initial therapy for active lupus nephritis, addressing the high unmet needs of the 120,000 U.S. patients suffering from this autoimmune disease.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
